Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial
Authors
Ida M. Gether (ORCID: https://orcid.org/0000-0001-8087-6421)
Anders Englund (ORCID: https://orcid.org/0009-0007-2954-7260)
David S. Mathiesen (ORCID: https://orcid.org/0000-0002-3545-5721)
Casper K. Nielsen (ORCID: https://orcid.org/0009-0000-8923-0643)
Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial
Ida M. Gether, Anders Englund, David S. Mathiesen, Casper K. Nielsen et al.
Journal
EClinicalMedicine
Topics
Diabetes Treatment and Management
article
Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial
Ida M. Gether, Anders Englund, David S. Mathiesen, Casper K. Nielsen, Thorir Gauti Pálsson, M Lukácová, Bolette Hartmann, Filip K. Knop, Julie L. Forman, Benjamin A.H. Jensen, Jens J. Holst, Asger B. Lund, Miriam G. Pedersen, Nicklas J. Johansen
article en
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 93
Institutions
University of Copenhagen (DK), Steno Diabetes Centers (DK), Novo Nordisk Foundation (DK), Gentofte Hospital (DK)